OCUL
Ocular Therapeutix, Inc.
stockNASDAQ
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix's lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company's earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.29 | 2026-10-01 | +3.36% | 1.245 |
| 1M | 11.37 | 2026-09-08 | -33.73% | 3.532 |
| 3M | 10.27 | 2026-07-08 | -26.63% | 1.611 |
| 6M | 8.42 | 2026-04-08 | -10.51% | 1.150 |
| 1Y | 11.91 | 2025-10-08 | -36.73% | 1.139 |
| 2Y | 9.32 | 2024-10-08 | -19.15% | — |
| 5Y | 9.75 | 2021-10-08 | -22.72% | 1.474 |
Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock price today is $7.54, and today's volume is 2,484,785. OCUL is up 4.219% today. The 30 day average volume is 3.11M. OCUL market cap is $1.65B with 219.62M shares outstanding.